ABI
WX

Adamant Biomedical Investments’s WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS WX Stock Holding History

Adamant Biomedical Investments’s Portfolio WX Stock Details WX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		$4.71M Buy
+140,000
New +$4.94M 1.13% 34

Other funds holding WX

Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CBOA
Commonwealth Bank of Australia Sydney, NSW, Australia $231M AUM
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return
CGI
Comgest Global Investors Paris, France $4.55B AUM 11.62% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Adamant Biomedical Investments's WX Position: Q4 2014 in Review

Adamant Biomedical Investments opened a new position in WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS (WX) in Q4 2014: 140,000 shares worth $4.71M. The stake represents 1.13% of the portfolio and ranks #34 among its holdings.

165 funds tracked by Wall St. Rank hold WX as of Q4 2014.

  • Adamant Biomedical Investments held 140,000 shares of WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS worth $4.71M as of Q4 2014.
  • WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS was a new Adamant Biomedical Investments position in Q4 2014.
  • WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS made up 1.13% of Adamant Biomedical Investments's portfolio in Q4 2014, its #34 holding.
  • 165 funds tracked by Wall St. Rank held WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS as of Q4 2014.

Based on Adamant Biomedical Investments's 13F filing for Q4 2014, filed 13 Feb 2015.